Home » Newsletters » BioWorld Science

BioWorld Science

April 10, 2006

View Archived Issues

Catumaxomab opsonization of lymphocytes feasible in refractory cancer

Celecoxib investigated in acute renal colic

Preclinical update on IPI-504 in MM, breast and pancreatic cancers

SuperGen completes acquisition of Montigen Pharmaceuticals

Pharmos prioritizes Vela compounds

Phase II study of ceftaroline in cSSSI completes enrollment

Vertex begins phase II program for VX-680

Intercell and Kirin Brewery to develop antibodies to treat pneumococcal infections

Adherex and NCI execute clinical trial agreement for ADH-1

REP-9 has potent antiviral activity against avian H5N1 influenza virus

ReNeuron to raise fund through international placing

Cytogen submits IND for CYT-500

Ganymed antibodies show efficacy in mouse tumor models

Kissei licenses rights to novel antidiabetic agent KGA-2727 to GlaxoSmithKline

EpiCept presents new SARS-CoV protease inhibitor

Roche reports new agents for thrombotic disorders

New agents for treating endocrine-related disorders disclosed in recent patents

Recent patents report new therapeutic agents for metabolic disorders

Orally active steroid from SRI proven to inhibit both angiogenesis and tumor growth

SMAC-mimetics induce apoptosis in combination with TRAIL in bladder cancer cells

Daytrana approved for use in ADHD

Potential development candidate for prostate cancer bone metastases presented by Lilly

Revlimid multiple myeloma MAA accepted for review in Europe

Pramipexole approved in Europe for restless legs syndrome

Novel chemopotentiating p38 MAPK inhibitor developed at Lilly

New PARG inhibitors for the treatment of Parkinson's disease identified

Interim phase I results reported for AAV-GAD gene therapy for Parkinson's disease

Novel series of apoptosis inducers presented by Maxim and Shire

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...